雷帕霉素在一名青少年粒单核细胞白血病患者中的应用：病例报告
Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report.
作者信息
Upadhyay Shivani Y, De Oliveira Satiro N, Moore Theodore B
机构信息
University of California, Los Angeles, CA, USA.
Cedars Sinai Medical Center, Los Angeles, CA, USA.
出版信息
J Investig Med High Impact Case Rep. 2017 Sep 8;5(3):2324709617728528. doi: 10.1177/2324709617728528. eCollection 2017 Jul-Sep.
Abstract
The relapse rate for children with juvenile myelomonocytic leukemia (JMML) status post hematopoietic stem cell transplantation (HSCT) approaches 50% within 5 years. Graft-versus-leukemia (GVL) is thought to play important role in the treatment of JMML. For this reason, careful management of immunosuppressive drugs after HSCT is crucial. This case report demonstrates that rapamycin and GVL represent a viable medical strategy for the management of pediatric patients with JMML who relapse following status post-HSCT.
摘要
青少年骨髓单核细胞白血病（JMML）患儿造血干细胞移植（HSCT）后5年内的复发率接近50%。移植物抗白血病（GVL）被认为在JMML的治疗中起重要作用。因此，HSCT后仔细管理免疫抑制药物至关重要。本病例报告表明，雷帕霉素和GVL是治疗HSCT后复发的JMML儿科患者的一种可行的医学策略。
相似文献
1
Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report.
J Investig Med High Impact Case Rep. 2017 Sep 8;5(3):2324709617728528. doi: 10.1177/2324709617728528. eCollection 2017 Jul-Sep.
2
Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2020 May;26(5):902-910. doi: 10.1016/j.bbmt.2019.11.029. Epub 2019 Nov 29.
3
[Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Aug;22(4):1058-62. doi: 10.7534/j.issn.1009-2137.2014.04.032.
4
[Clinical Study on Treatment of Juvenile Myelomonocytic Leukemia with Haploidentical-Hematopoietic Stem Cell Transplantation].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Oct;25(5):1524-1527. doi: 10.7534/j.issn.1009-2137.2017.05.043.
5
Current Treatment of Juvenile Myelomonocytic Leukemia.
J Clin Med. 2021 Jul 13;10(14):3084. doi: 10.3390/jcm10143084.
6
Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.
Transplant Cell Ther. 2021 Nov;27(11):926.e1-926.e10. doi: 10.1016/j.jtct.2021.08.009. Epub 2021 Aug 15.
7
Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report.
Medicine (Baltimore). 2020 Dec 11;99(50):e23606. doi: 10.1097/MD.0000000000023606.
8
Successful treatment of juvenile myelomonocytic leukemia relapsing after stem cell transplantation using donor lymphocyte infusion.
Blood. 2003 Mar 1;101(5):1713-4. doi: 10.1182/blood-2002-07-2011. Epub 2002 Oct 3.
9
Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations.
Paediatr Drugs. 2010;12(1):11-21. doi: 10.2165/11316200-000000000-00000.
10
Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study.
Front Immunol. 2024 Aug 26;15:1426640. doi: 10.3389/fimmu.2024.1426640. eCollection 2024.
引用本文的文献
1
Pediatric Neoplasms Presenting with Monocytosis.
Curr Hematol Malig Rep. 2021 Jun;16(3):235-246. doi: 10.1007/s11899-021-00611-x. Epub 2021 Feb 25.
2
[Clinical and genetic analyses of juvenile myelomonocytic leukemia].
Zhongguo Dang Dai Er Ke Za Zhi. 2019 Apr;21(4):365-369. doi: 10.7499/j.issn.1008-8830.2019.04.012.
3
[Advances in the treatment of juvenile myelomonocytic leukemia].
Zhongguo Dang Dai Er Ke Za Zhi. 2018 Nov;20(11):958-963. doi: 10.7499/j.issn.1008-8830.2018.11.016.
本文引用的文献
1
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
Pediatr Blood Cancer. 2015 Apr;62(4):629-36. doi: 10.1002/pbc.25342. Epub 2014 Dec 8.
2
How I treat juvenile myelomonocytic leukemia.
Blood. 2015 Feb 12;125(7):1083-90. doi: 10.1182/blood-2014-08-550483. Epub 2015 Jan 6.
3
Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.
Int J Hematol. 2015 Feb;101(2):184-90. doi: 10.1007/s12185-014-1715-7. Epub 2014 Dec 11.
4
Successful second unrelated cord blood transplantation in a child with juvenile myelomonocytic leukemia.
Pediatr Transplant. 2014 Sep;18(6):651-2. doi: 10.1111/petr.12312. Epub 2014 Jun 30.
5
Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.
Br J Haematol. 2011 Mar;152(6):677-87. doi: 10.1111/j.1365-2141.2010.08525.x.
6
PTEN deficiency is a common defect in juvenile myelomonocytic leukemia.
Leuk Res. 2009 May;33(5):671-7. doi: 10.1016/j.leukres.2008.09.036. Epub 2008 Nov 17.
7
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.
Drug Resist Updat. 2008 Feb-Apr;11(1-2):32-50. doi: 10.1016/j.drup.2007.11.003. Epub 2007 Dec 31.
8
Graft versus leukemia effect against juvenile myelomonocytic leukemia after unrelated cord blood transplantation.
Pediatr Blood Cancer. 2008 Mar;50(3):665-7. doi: 10.1002/pbc.21200.
9
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial.
Blood. 2005 Jan 1;105(1):410-9. doi: 10.1182/blood-2004-05-1944. Epub 2004 Sep 7.
10
Successful treatment of juvenile myelomonocytic leukemia relapsing after stem cell transplantation using donor lymphocyte infusion.
Blood. 2003 Mar 1;101(5):1713-4. doi: 10.1182/blood-2002-07-2011. Epub 2002 Oct 3.
Zotero 插件